Market accessOfficial

Rimactan 300 mg rifampicin capsules face Danish supply problems through end of 2026

🇩🇰 DKMA · Tue 27 Oct 2026

DKMA has updated its notice on Sandoz's Rimactan 300 mg capsules, citing increased demand and an expected disruption from mid-February to the end of December 2026.

The Danish Medicines Agency (DKMA) has updated its supply notice for Rimactan 300 mg hard capsules from Sandoz A/S. The notice was first published on 25 February 2026 and revised on 27 October 2026.

The product contains the active substance rifampicin (ATC code J04AB02). DKMA states that there are current problems with its supply in Denmark.

The agency gives the expected period of disruption as mid-February to the end of December 2026. The stated cause is increased sales or demand.

The notice does not describe alternative products or substitution measures, and it does not say what changed in the latest update. DKMA directs questions about the current status to Sandoz A/S.

What it means for your team

  • Supply planning teams should note that the disruption is expected to run until the end of December 2026, according to DKMA.
  • The notice cites increased sales or demand as the cause, not a quality or safety issue.
  • Teams needing up-to-date availability information should contact Sandoz A/S, as DKMA directs.
  • Check the full DKMA notice for any further changes, as the summary gives no detail on the October update.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Market access All →